FOX8 Cleveland

Positive Phase 3 Dupixent® (dupilumab) Data in Children 6 Months to 5 Years with Moderate-to-severe Atopic Dermatitis Featured in RAD 2021 Late-breaking Session

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced detailed positive Phase 3 results that showed adding Dupixent ® (dupilumab) to standard-of-care topical corticosteroids (TCS) ...
FiercePharma

AbbVie takes 2022 TV drug ad spending crown with Rinvoq, knocking last year's winner Dupixent into 2nd place

As AbbVie moved away from promotional spend on its aging megablockbuster Humira at the same time Sanofi and Regeneron stepped up their TV campaigns for Dupixent in 2021, you might be forgiven for ...
FiercePharma

Dupixent dethroned as AbbVie rival Rinvoq shoots to the top of pharma’s TV ad spenders

Sanofi and Regeneron’s immunology blockbuster Dupixent had been on a mini streak as king of the pharma airwaves but was knocked off its perch in June by AbbVie’s competing drug Rinvoq. That’s ...
Reuters

Sanofi's Dupixent gets U.S. approval to treat eczema in young children

June 7 (Reuters) - The U.S. Food and Drug Administration approved the use of Sanofi (SASY.PA), opens new tab and Regeneron Pharmaceuticals Inc's (REGN.O), opens new tab anti-inflammation drug Dupixent ...
Nasdaq

Press Release: Dupixent® (dupilumab) sBLA for treatment of eosinophilic esophagitis in children aged 1 to 11 accepted for FDA Priority Review

If approved, Dupixent would be the first and only treatment indicated in the U.S. for children aged 1- 11 with eosinophilic esophagitis, a disease driven by type 2 inflammation that impacts the ...
Hosted on MSN

EMA approves Sanofi/Regeneron’s Dupixent for young EoE patients

The European Medicines Agency (EMA) approved Sanofi/Regeneron’s Dupixent (dupilumab) to treat eosinophilic esophagitis (EoE) in children as young as one. The approval extends the use of Dupixent to ...